The need for a credible pharmacokinetic profile workup.

The principles

Recommendation 4: A comprehensive pharmacokinetic profile must be developed and fully reported. 

Barbara M’s recent comment on the removal of a cancerous kidney from her son provides a sad but perfect example as to why ARI vaccines should be thoroughly developed, assessed impartially and licensed if they meet positive risk-benefit and cost-effectiveness criteria.

Be clear: Barbara did not directly link her son’s cancer to exposure to Covid vaccines, but as readers well know, there are countless sources that do so. However, do they or do they not cause, trigger or accelerate some or all types of cancer?

The short answer is that we do not really know, and this is the problem.

In the linked post, we present evidence of the sketchy nature of the pharmacokinetics (PK) of Comirnaty at the time of licensing and since then. The evidence was examined in our Comirnaty series from posts 9 to 9f, and it does not make for easy or comfortable reading.

It’s important to note that we did not consider jour…